HomeCompareBSPM vs JNJ

BSPM vs JNJ: Dividend Comparison 2026

BSPM yields 2000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BSPM wins by $4.879226400974806e+39M in total portfolio value
10 years
BSPM
BSPM
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full BSPM calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — BSPM vs JNJ

📍 BSPM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSPMJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSPM + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSPM pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSPM
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, BSPM beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSPM + JNJ for your $10,000?

BSPM: 50%JNJ: 50%
100% JNJ50/50100% BSPM
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BSPM
No analyst data
Altman Z
0.0
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSPM buys
0
JNJ buys
0
No recent congressional trades found for BSPM or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSPMJNJ
Forward yield2000000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.879226400974806e+39M$30.5K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$4.879195005460081e+39M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BSPM vs JNJ ($10,000, DRIP)

YearBSPM PortfolioBSPM Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,594$274.49+$200.00MBSPM
2$3,738,731,768,458$3,738,517,757,009.35$11,294$360.69+$3738731.76MBSPM
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,133$476.91+$65315062866.92MBSPM
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,156$635.42+$1066400830062625.00MBSPM
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$14,432$854.61+$16272182796453826560.00MBSPM
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,056$1,162.76+$2.3205424011366188e+23MBSPM
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,175$1,604.53+$3.0927990661046884e+27MBSPM
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$21,009$2,252.68+$3.8524105697352695e+31MBSPM
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$24,911$3,229.73+$4.484688260147987e+35MBSPM
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.879226400974806e+39MBSPM

BSPM vs JNJ: Complete Analysis 2026

BSPMStock

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

Full BSPM Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BSPM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSPM vs SCHDBSPM vs JEPIBSPM vs OBSPM vs KOBSPM vs MAINBSPM vs ABBVBSPM vs MRKBSPM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.